Company intelligence / Profile preview
POLYGON Therapeutics
Paris, Île-de-France, Francepolygon.care ↗
- Ownership
- Private
- Employees
- ~9
- Development stage
- Preclinical
01
Overview
Polygon’s lead candidate, PLG-101, has met all pre-clinical milestones and is advancing to clinical development with a first-in-human Phase 1 trial scheduled for late 2025. The company has demonstrated promising results in both in vitro and in vivo studies and is finalizing manufacturing scale-up for clinical trials. Seed financing of $7.5M was recently completed to support this transition.[6]
- Therapeutic areas
- Cardiovascular
- Modalities
- Monoclonal antibodies (mAbs)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on POLYGON Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on POLYGON Therapeutics.